fda warning letter glp-1 solution september 9 2025 Last month, the issued 25 letters to telehealth companies over what it called false or misleading claims about compounded medications. Read more at the link in the comments below FDA Targets GLP-1 and Peptide

A specific MSA-DH activity of 7.5 0.2 mol min 1 mg 1 was determined

Effect of anthocyanins on gut health markers, Firmicutes-Bacteroidetes ratio and short-chain fatty acids: a systematic review via meta-analysis

Inulin impacts tumorigenesis promotion by colibactin-producing escherichia coli in apc(Min/+) mice

Blue Cross and BCN will continue covering GLP-1s prescribed to treat Type 2 diabetes, including the medications Ozempic, Mounjaro, Rybelsus and Victoza

This supports previous work by researchers at the University of California, Berkeley, and the Children's Hospital Oakland Research Institute led by Professor Bruce Ames